Obesity/Glucose Metabolic Disorders - Eos SENOLYTIX

Obesity/Glucose Metabolic Disorders

Greater lean-body-mass decline with tirzepatide than semaglutide in routine care revealed by body-composition digital phenotyping

April 13, 2026

Sustained visceral fat loss is associated with attenuated brain atrophy and improved cognitive function in late midlife

March 4, 2026

Unintended risks of sarcopenic obesity during weight-loss interventions in older people

February 5, 2026

Muscle-preserving therapies in the era of pharmacological weight loss

January 2, 2026

Two‑phase model of ageing in mice for improved identification of age‑related and late life metabolic decline

October 22, 2025

Effect of glucagon-like peptide-1 receptor agonists and co-agonists on body composition: Systematic review and network meta-analysis

December 22, 2024

Inhibition Of IL-11 Signalling Extends Mammalian Healthspan and Lifespan

June 11, 2024

Prophylactic and Long-Lasting Efficacy of Senolytic CAR T Cells Against Age-Related Metabolic Dysfunction

January 24, 2024

Once-Weekly Semaglutide in Adults with Overweight or Obesity

March 18, 2021

Targeting Senescent Cells Alleviates Obesity‐Induced Metabolic Dysfunction

January 25, 2019

Categories

Archives

© 2026 Eos SENOLYTIX.